+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route of Administration, By Distribution Channel, By Region, and Segment Forecasts, 2021-2028

  • ID: 5457623
  • Report
  • October 2021
  • Region: Global
  • 120 Pages
  • Grand View Research

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Biogen
  • Lilly
  • Merck & Co., Inc.
  • Novartis AG
The global inflammatory bowel disease treatment market size is expected to reach USD 27.8 billion by 2028. The market is expected to expand at a CAGR of 4.8% from 2021 to 2028. Increasing awareness about the disease, rise in geriatric population, and favorable initiatives undertaken by regulatory bodies are anticipated to drive the market growth over the forecast period. For instance, in January 2020, the U.S. FDA allowed ABIVAX to conduct a phase 2B clinical trial of ABX464 on U.S. patients living with moderate-to-severe ulcerative colitis.



Increasing adoption of strategies such as new product development and expansion is expected to drive market growth. For instance, in June 2020, Takeda Pharmaceutical received U.S. FDA approval to manufacture Entyvio (vedolizumab) in its U.S.-based manufacturing facility. The approval is expected to support the growing demand for the drug in the U.S. and nearby countries. Moreover, Takeda pharmaceutical is heavily investing in the development of the market in China.

An increase in initiatives undertaken by various organizations to tackle the challenges in the development of novel therapy development is expected to boost the market growth in the coming years. For instance, in May 2019, Crohn’s and Colitis Foundation released a five-year plan to mark unmet needs in IBD research and development and IBD treatment. Moreover, European Chronic Disease Alliance has taken many steps to improve the life of patients living with inflammatory bowel disease.

Implementation of favorable healthcare policies in developed countries is increasing the prescription of novel drugs for the treatment of inflammatory bowel disease. For instance, in September 2017, the Australian Therapeutic Goods Administration listed Stelara on Pharmaceutical Benefits Scheme (PBS) for the treatment of the severe condition of Crohn’s disease in adults. PBS listing of Stelara will increase the prescription of the drug in the country.

The clinical-stage companies involved in the development of innovative treatments for IBD are expected to fuel the market growth. For instance, Germany-based Sterna Biologicals, a clinical-stage company is conducting phase IIb clinical trials for the treatment of ulcerative colitis. Moreover, Galapagos NV, a research-based company is conducting phase 3 clinical trials for its JAK inhibitor, Filgotinib, for the treatment of Crohn’s disease and ulcerative colitis. The product is expected to receive approval for IBD treatment in the next 2 to 3 years.

Regulatory bodies are encouraging the manufacturers to increase research initiatives by introducing programs such as U.S. Orphan Drug Program. For instance, in August 2017, InDex Pharmaceuticals Holding AB’s drug candidate cobitolimod (intended for the treatment of ulcerative colitis) received orphan drug designation by the U.S. FDA. In August 2019, the drug met the primary endpoints of phase 2b clinical studies for the development of ulcerative colitis treatment.

Inflammatory Bowel Disease Treatment Market Report Highlights

  • In 2020, Crohn’s disease accounted for the largest revenue share of more than 60.0% and is anticipated to maintain its dominance over the forecast period.
  • Based on drug class, the TNF inhibitors segment dominated the market in 2020 owing to the high prescription rate of Humira and Remicade globally.
  • Pipeline candidates in the JAK inhibitors drug class such as upadacitinib, tofacitinib, and filgotinib are anticipated to drive the segment growth at the fastest rate from 2021 to 2028.
  • The oral drugs segment is anticipated to grow at the fastest rate over the forecast period owing to an increase in approval of pipeline drugs such as upadacitinib, etrasimod, ozanimod, and others.
  • Asia Pacific is expected to witness the fastest growth in the coming years owing to rising approval of biosimilars and increasing awareness related to the disease.
  • North America held the largest market owing to the adoption of biologics for IBD treatment and better reimbursement scenarios in the country.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Biogen
  • Lilly
  • Merck & Co., Inc.
  • Novartis AG
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased database:
1.3.2 internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
1.8.3 Objective 3
1.8.4 Objective 4

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Inflammatory Bowel Disease Treatment Market Variables, Trends & Scope
3.1 Inflammatory Bowel Disease Treatment: Market Lineage Outlook
3.1.1 Related/ancillary market outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising prevalence of Crohn’s disease and ulcerative colitis
3.2.1.2 Robust Product Pipeline
3.2.1.3 Increasing geriatric population
3.2.1.4 Emergence of biosimilars
3.2.1.5 Involvement of regulatory bodies for funding and designation
3.2.2 Market Restraint Analysis
3.2.2.1 High Cost OF Treatment
3.2.2.2 Lack of early diagnosis
3.3 Penetration and Growth Prospect Mapping
3.4 Inflammatory bowel disease treatment Market Analysis Tools
3.4.1 PESTEL Analysis
3.4.2 Porter’s Five Forces Analysis

Chapter 4 Inflammatory Bowel Disease Treatment Market - Segment Analysis, By Type, 2017 - 2028 (USD Million)
4.1 Definitions & Scope
4.2 Type Market Share Analysis, 2020 & 2028
4.3 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.3.1 Crohn’s disease
4.3.1.1 Crohn’s disease market estimates and forecast, 2017 - 2028 (USD Million)
4.3.2 Ulcerative colitis
4.3.2.1 Ulcerative colitis market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 5 Inflammatory Bowel Disease Treatment Market - Segment Analysis, By Drug Class, 2017 - 2028 (USD Million)
5.1 Definitions & Scope
5.2 Drug Class Market Share Analysis, 2020 & 2028
5.3 Market Size & Forecasts and Trend Analysis, 2017 to 2028
5.3.1 Aminosalicylates
5.3.1.1 Aminosalicylates market estimates and forecast, 2017 - 2028 (USD Million)
5.3.2 Corticosteroids
5.3.2.1 Corticosteroids market estimates and forecast, 2017 - 2028 (USD Million)
5.3.3 TNF inhibitors
5.3.3.1 TNF inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
5.3.4 IL inhibitors
5.3.4.1 IL inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
5.3.5 Anti-integrin
5.3.5.1 Anti-integrin market estimates and forecast, 2017 - 2028 (USD Million)
5.3.6 JAK inhibitors
5.3.6.1 JAK inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
5.3.7 Others
5.3.7.1 Others market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 6 Inflammatory Bowel Disease Treatment Market - Segment Analysis, By Distribution Channel, 2017 - 2028 (USD Million)
6.1 Definitions & Scope
6.2 Distribution Channel Market Share Analysis, 2020 & 2028
6.3 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.3.1 Hospital Pharmacy
6.3.1.1 Hospital Pharmacy Market, 2017 - 2028 (USD Million)
6.3.2 Retail Pharmacy
6.3.2.1 Retail Pharmacy Market, 2017 - 2028 (USD Million)
6.3.3 Online Pharmacy
6.3.3.1 Online Pharmacy Market, 2017 - 2028 (USD Million)

Chapter 7 Inflammatory Bowel Disease Treatment Market - Segment Analysis, By Route of Administration, 2017 - 2028 (USD Million)
7.1 Definitions & Scope
7.2 Route of Administration Market Share Analysis, 2020 & 2028
7.3 Market Size & Forecasts and Trend Analyses, 2017 to 2028
7.3.1 Oral
7.3.1.1 Oral Market, 2017 - 2028 (USD Million)
7.3.2 InjecTable
7.3.2.1 InjecTable Market, 2017 - 2028 (USD Million)

Chapter 8 Inflammatory Bowel Disease Treatment Market - Segment Analysis, By Region, 2017 - 2028 (USD Million)
8.1 Regional Market Share Analysis, 2020 & 2028
8.2 SWOT Analysis, By Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 MEA
8.3 North America
8.3.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
8.3.3 Canada
8.3.3.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
8.4 Europe
8.4.1 Europe market estimates and forecast, 2017 - 2028 (USD Million)
8.4.2 U.K.
8.4.2.1 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
8.4.3 Germany
8.4.3.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
8.4.4 Spain
8.4.4.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
8.4.5 France
8.4.5.1 France market estimates and forecast, 2017 - 2028 (USD Million)
8.4.6 Italy
8.4.6.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
8.5 Asia Pacific
8.5.1 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
8.5.2 Japan
8.5.2.1 Japan market estimates and forecast, 2017 - 2028 (USD Million)
8.5.3 China
8.5.3.1 China market estimates and forecast, 2017 - 2028 (USD Million)
8.5.4 India
8.5.4.1 India market estimates and forecast, 2017 - 2028 (USD Million)
8.5.5 South Korea
8.5.5.1 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
8.5.6 Singapore
8.5.6.1 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
8.5.7 Australia
8.5.7.1 Australia market estimates and forecast, 2017 - 2028 (USD Million)
8.6 Latin America
8.6.1 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
8.6.2 Brazil
8.6.2.1 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
8.6.3 Mexico
8.6.3.1 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
8.6.4 Argentina
8.6.4.1 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
8.7 Middle East and Africa
8.7.1 Middle East and Africa market estimates and forecast, 2017 - 2028 (USD Million)
8.7.2 South Africa
8.7.2.1 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
8.7.3 United Arab Emirates (UAE)
8.7.3.1 United Arab Emirates (UAE) market estimates and forecast, 2017 - 2028 (USD Million)
8.7.4 Saudi Arabia
8.7.4.1 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 9 Competitive & Vendor Landscape
9.1 Recent developments & impact analysis, by key market participants
9.1.1 Ansoff matrix
9.2 Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
9.2.1 Innovators
9.2.2 Market Leaders
9.3 Vendor Landscape
9.3.1 Key customers
9.3.2 Key company market share analysis, 2020
9.4 Public Companies
9.4.1 Company market position analysis
9.5 Synergy Analysis: Major Deals & Strategic Alliances
9.5.1 New Product Launch
9.5.2 Acquisition
9.5.3 Expansion
9.5.4 Partnerships
9.5.5 Marketing & Promotions
9.6 Strategic Framework
9.7 Company Profiles
9.7.1 AbbVie Inc.
9.7.1.1 Company overview
9.7.1.2 Financial Performance
9.7.1.3 Product benchmarking
9.7.1.4 Strategic initiatives
9.7.2 Biogen
9.7.2.1 Company overview
9.7.2.2 Financial Performance
9.7.2.3 Product benchmarking
9.7.2.4 Strategic initiatives
9.7.3 Johnson & Johnson Services, Inc.
9.7.3.1 Company overview
9.7.3.2 Financial Performance
9.7.3.3 Product benchmarking
9.7.3.4 Strategic initiatives
9.7.4 Amgen Inc.
9.7.4.1 Company overview
9.7.4.2 Financial Performance
9.7.4.3 Product benchmarking
9.7.4.4 Strategic initiatives
9.7.5 UCB S.A.
9.7.5.1 Company Overview
9.7.5.2 Financial Performance
9.7.5.3 Product benchmarking
9.7.5.4 Strategic Initiatives
9.7.6 Novartis AG
9.7.6.1 Company overview
9.7.6.2 Celgene Corporation
9.7.6.3 Financial Performance
9.7.6.4 Product benchmarking
9.7.6.5 Strategic initiatives
9.7.7 Takeda Pharmaceutical Company Limited
9.7.7.1 Company Overview
9.7.7.2 Financial Performance
9.7.7.3 Product benchmarking
9.7.7.4 Strategic initiatives
9.7.8 Merck & Co., Inc.
9.7.8.1 Company Overview
9.7.8.2 Financial Performance
9.7.8.3 Product benchmarking
9.7.8.4 Strategic initiatives
9.7.9 Pfizer Inc.
9.7.9.1 Company Overview
9.7.9.2 Financial Performance
9.7.9.3 Product Benchmarking
9.7.9.4 Strategic Initiatives
9.7.10 Lilly
9.7.10.1 Company Overview
9.7.10.2 Financial Performance
9.7.10.3 Product Benchmarking
9.7.10.4 Strategic initiatives

List of Tables
Table 1 List of Secondary Sources
Table 2 Some of the Potential Phase 3 Pipeline Drugs
Table 3 List of Approved Biosimilars for Treating IBD
Table 4 Regulatory Scenario
Table 5 Lead Products and Their Average Selling Price
Table 6 Number of Potential IBD Patients, by Region, (2017-2028) (in thousands)
Table 7 Leading Market Players
Table 8 North America IBD Market, By Country, 2017-2028 (USD Million)
Table 9 North America IBD Market, By Type, 2017-2028 (USD Million)
Table 10 North America IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 11 North America IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 12 North America IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 13 U.S. IBD Market, By Type, 2017-2028 (USD Million)
Table 14 U.S. IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 15 U.S. IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 16 U.S. IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 17 Canada IBD Market, By Type, 2017-2028 (USD Million)
Table 18 Canada IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 19 Canada IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 20 Canada IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 21 Europe IBD Market, By Country, 2017-2028 (USD Million)
Table 22 Europe IBD Market, By Type, 2017-2028 (USD Million)
Table 23 Europe IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 24 Europe IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 25 Europe IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 26 U.K. IBD Market, By Type, 2017-2028 (USD Million)
Table 27 U.K. IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 28 U.K. IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 29 U.K. IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 30 Germany IBD Market, By Type, 2017-2028 (USD Million)
Table 31 Germany IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 32 Germany IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 33 Germany IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 34 France IBD Market, By Type, 2017-2028 (USD Million)
Table 35 France IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 36 France IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 37 France IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 38 Spain IBD Market, By Type, 2017-2028 (USD Million)
Table 39 Spain IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 40 Spain IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 41 Spain IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 42 Italy IBD Market, By Type, 2017-2028 (USD Million)
Table 43 Italy IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 44 Italy IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 45 Italy IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 46 Asia Pacific IBD Market, By Country, 2017-2028 (USD Million)
Table 47 Asia Pacific IBD Market, By Type, 2017-2028 (USD Million)
Table 48 Asia Pacific IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 49 Asia Pacific IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 50 Asia Pacific IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 51 Japan IBD Market, By Type, 2017-2028 (USD Million)
Table 52 Japan IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 53 Japan IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 54 Japan IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 55 China IBD Market, By Type, 2017-2028 (USD Million)
Table 56 China IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 57 China IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 58 China IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 59 India IBD Market, By Type, 2017-2028 (USD Million)
Table 60 India IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 61 India IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 62 India IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 63 South Korea IBD Market, By Type, 2017-2028 (USD Million)
Table 64 South Korea IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 65 South Korea IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 66 South Korea IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 67 Australia IBD Market, By Type, 2017-2028 (USD Million)
Table 68 Australia IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 69 Australia IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 70 Australia IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 71 Singapore IBD Market, By Type, 2017-2028 (USD Million)
Table 72 Singapore IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 73 Singapore IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 74 Singapore IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 75 Latin America IBD Market, By Country, 2017-2028 (USD Million)
Table 76 Latin America IBD Market, By Type, 2017-2028 (USD Million)
Table 77 Latina America IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 78 Latin America IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 79 Latin America IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 80 Brazil IBD Market, By Type, 2017-2028 (USD Million)
Table 81 Brazil IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 82 Brazil IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 83 Brazil IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 84 Mexico IBD Market, By Type, 2017-2028 (USD Million)
Table 85 Mexico IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 86 Mexico IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 87 Mexico IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 88 Argentina IBD Market, By Type, 2017-2028 (USD Million)
Table 89 Argentina IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 90 Argentina IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 91 Argentina IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 92 Middle East & Africa IBD Market, By Country, 2017-2028 (USD Million)
Table 93 Middle East & Africa IBD Market, By Type, 2017-2028 (USD Million)
Table 94 Middle East & Africa IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 95 Middle East & Africa IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 96 Middle East & Africa IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 97 South Africa IBD Market, By Type, 2017-2028 (USD Million)
Table 98 South Africa IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 99 South Africa IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 100 South Africa IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 101 Saudi Arabia IBD Market, By Type, 2017-2028 (USD Million)
Table 102 Saudi Arabia IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 103 Saudi Arabia IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 104 Saudi Arabia IBD Market, By Distribution Channel, 2017-2028 (USD Million)
Table 105 UAE IBD Market, By Type, 2017-2028 (USD Million)
Table 106 UAE IBD Market, By Drug Class, 2017-2028 (USD Million)
Table 107 UAE IBD Market, By Route of Administration, 2017-2028 (USD Million)
Table 108 UAE IBD Market, By Distribution Channel, 2017-2028 (USD Million)

List of Figures
Fig. 1 Inflammatory bowel disease treatment market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Inflammatory bowel disease treatment market snapshot
Fig. 10 Parent Market Outlook
Fig. 11 Inflammatory bowel disease treatment market driver impact
Fig. 12 Geriatric population in 2019 and 2050
Fig. 13 Inflammatory bowel disease treatment market restraint impact
Fig. 14 Penetration and growth prospect mapping
Fig. 15 SWOT analysis, by factor (Political & legal, economic and technological)
Fig. 16 Porter’s five forces analysis
Fig. 17 Inflammatory bowel disease treatment market: Type outlook and key takeaways
Fig. 18 Inflammatory bowel disease treatment market: Type movement analysis
Fig. 19 Crohn's disease market estimates and forecast, 2017-2028 (USD Million)
Fig. 20 Ulcerative colitis market estimates and forecast, 2017-2028 (USD Million)
Fig. 21 Inflammatory bowel disease treatment market: Drug class outlook and key takeaways
Fig. 22 Inflammatory bowel disease treatment market: Drug class movement analysis
Fig. 23 Aminosalicylates market estimates and forecast, 2017-2028 (USD Million)
Fig. 24 Corticosteroids market estimates and forecast, 2017-2028 (USD Million)
Fig. 25 TNF inhibitors market estimates and forecast, 2017-2028 (USD Million)
Fig. 26 IL inhibitors market estimates and forecast, 2017-2028 (USD Million)
Fig. 27 Anti-integrin market estimates and forecast, 2017-2028 (USD Million)
Fig. 28 JAK inhibitors market estimates and forecast, 2017-2028 (USD Million)
Fig. 29 Others market estimates and forecast, 2017-2028 (USD Million)
Fig. 30 Inflammatory bowel disease treatment market: Route of administration outlook and key takeaways
Fig. 31 Inflammatory bowel disease treatment market: Route of administration movement analysis
Fig. 32 Oral market estimates and forecast, 2017-2028 (USD Million)
Fig. 33 InjecTable market estimates and forecast, 2017-2028 (USD Million)
Fig. 34 Inflammatory bowel disease treatment market: Distribution channel outlook and key takeaways
Fig. 35 Inflammatory bowel disease treatment market: Distribution channel movement analysis
Fig. 36 Hospital pharmacy market estimates and forecast, 2017-2028 (USD Million)
Fig. 37 Retail pharmacy market estimates and forecast, 2017-2028 (USD Million)
Fig. 38 Online pharmacy market estimates and forecast, 2017-2028 (USD Million)
Fig. 39 Inflammatory bowel disease treatment market: regional outlook and key takeaways
Fig. 40 Regional outlook, 2020 & 2028
Fig. 41 North America
Fig. 42 Europe
Fig. 43 Asia Pacific
Fig. 44 Latin America
Fig. 45 MEA
Fig. 46 North America
Fig. 47 North America market estimates and forecast, 2017-2028 (USD Million)
Fig. 48 U.S.
Fig. 49 U.S. market estimates and forecast, 2017-2028 (USD Million)
Fig. 50 Canada
Fig. 51 Canada market estimates and forecast, 2017-2028 (USD Million)
Fig. 52 Europe
Fig. 53 Europe market estimates and forecast, 2017-2028 (USD Million)
Fig. 54 U.K.
Fig. 55 U.K. market estimates and forecast, 2017-2028 (USD Million)
Fig. 56 Germany
Fig. 57 Germany market estimates and forecast, 2017-2028 (USD Million)
Fig. 58 Spain
Fig. 59 Spain market estimates and forecast, 2017-2028 (USD Million)
Fig. 60 France
Fig. 61 France market estimates and forecast, 2017-2028 (USD Million)
Fig. 62 Italy
Fig. 63 Italy market estimates and forecast, 2017-2028 (USD Million)
Fig. 64 Asia Pacific
Fig. 65 Asia Pacific market estimates and forecast, 2017-2028 (USD Million)
Fig. 66 Japan
Fig. 67 Japan market estimates and forecast, 2017-2028 (USD Million)
Fig. 68 China
Fig. 69 China market estimates and forecast, 2017-2028 (USD Million)
Fig. 70 India
Fig. 71 India market estimates and forecast, 2017-2028 (USD Million)
Fig. 72 South Korea
Fig. 73 South Korea market estimates and forecast, 2017-2028 (USD Million)
Fig. 74 Singapore
Fig. 75 Singapore market estimates and forecast, 2017-2028 (USD Million)
Fig. 76 Australia
Fig. 77 Australia market estimates and forecast, 2017-2028 (USD Million)
Fig. 78 Latin America
Fig. 79 Latin America market estimates and forecast, 2017-2028 (USD Million)
Fig. 80 Brazil
Fig. 81 Brazil market estimates and forecast, 2017-2028 (USD Million)
Fig. 82 Mexico
Fig. 83 Mexico market estimates and forecast, 2017-2028 (USD Million)
Fig. 84 Argentina
Fig. 85 Argentina market estimates and forecast, 2017-2028 (USD Million)
Fig. 86 Middle East & Africa
Fig. 87 MEA market estimates and forecast, 2017-2028 (USD Million)
Fig. 88 South Africa
Fig. 89 South Africa market estimates and forecast, 2017-2028 (USD Million)
Fig. 90 United Arab Emirates (UAE)
Fig. 91 United Arab Emirates (UAE) market estimates and forecast, 2017-2028 (USD Million)
Fig. 92 Saudi Arabia
Fig. 93 Saudi Arabia market estimates and forecast, 2017-2028 (USD Million)
Fig. 94 Ansoff Matrix
Fig. 95 Heat map analysis
Fig. 96 Company market share analysis, 2020
Fig. 97 Company market position analysis
Fig. 98 Company market position analysis
Fig. 99 Market differentiators
Fig. 100 Strategy mapping
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Biogen
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Lilly
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll